Effect of H 1 -antagonist Dithiaden® on human PMN-leukocyte aggregation and chemiluminescence is stimulus-dependent

Inflammation Research

Volumn 51, Issue 11, 2002, Pages 557-562

  Nosal R ^a   Drabikova K ^a   Ciz M ^b   Lojek, A ^b   Danihelova E ^c  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c Inst Haematol/Transfusiology   (Slovakia)

Author keywords

Aggregation; Chemiluminescence; Dithiaden ; Histamine; PMN leukocytes

Indexed keywords

CALCIMYCIN; CALCIUM ION; DITHIADEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PHORBOL 13 ACETATE 12 MYRISTATE; ZYMOSAN; BENZOTHIEPIN DERIVATIVE; DIAGNOSTIC AGENT; IONOPHORE; LUMINOL; REACTIVE OXYGEN METABOLITE;

ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CONTROLLED STUDY; DOSE RESPONSE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOCYTE AGGREGATION; NEUTROPHIL; CELL AGGREGATION; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM;

BENZOTHIEPINS; CALCIMYCIN; CELL AGGREGATION; CHEMILUMINESCENT MEASUREMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; IONOPHORES; LUMINOL; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; REACTIVE OXYGEN SPECIES; TETRADECANOYLPHORBOL ACETATE; ZYMOSAN;

EID: 0036866145     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00012427     Document Type: Article

References (40)

1. Benbarek H, Mouithys-Mickalad A, Deby-Dupont G, Deby C, Grulke S, Nemmar A, Lamy M, Serteun D. High concentrations of histamine stimulate equine polymorphonuclear neutrophils to produce reactive oxygen species. Inflamm Res 1999; 48: 594-601.
2. Berthon B, Tandou G, Gombettes L, Czarlewski W, Carme-Leroy A, Marchand F et al. In vitro inhibition by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells. Biochem Pharmacol 1994; 47: 789-94.
3. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968; 21: 77-90.
4. Bradbury AW, Murie JA, Ruckley V. Role of the leukocyte in the pathogenesis of vascular disease. Br J Surg 1993; 80: 1503-12.
5. 2 -receptors. Naun Schmied Arch Pharmacol 1989; 340: 671-8.
6. Ching TL, Koelemij JG, Bast A. The effect of histamine on the oxidative burst of HL 80 cells before and after exposure to reactive oxygen species. Inflamm Res 1995; 44: 99-104.
7. 1 -receptor effects of antihistamines. Clin Exper Allergy 1999; 29, Suppl.3: 39-48.
8. 1 -antihistamines and inflammation. Clin Exper Allergy 2001; 31: 1341-3.
9. 1 -receptor antagonists: Effect on leukocytes, myth or reality. Clin Exper Allergy 1999; 29: 60-3.
10. 2 ) and chemiluminescence in alveolar macrophages. Nature 1979; 278: 454-6.
11. 1 -histamine antagonist Dithiaden® on the interaction between stimulated human polymorphonuclear leukocytes and platelets. Fund Clin Pharmacol 1999; 13: 144.
12. Drábiková K, Jančinová V, Nosál R, Danihelová E. Human blood platelets, PMN leukocyets and their interactions in vitro. Responses to selective and non-selective stimuli. Gen Physiol Biophys 2000, 19: 393-404.
13. Edwards ST. The generation and recognition of neutrophil-activating factors: Structure and function of neutrophil receptors. In: Biochemistry and Physiology of the Neutrophil. ST Edwards (Ed.) Cambridge University Press 1994; p. 77-124.
14. Francis JW, Tood RE, Bower LA, Petty HR. Histamine inhibits cell spreading and C3bi receptor clustering and diminishes hydrogen peroxide production by adherent human neutrophils. J Cell Biol 1991; 147: 128-37.
15. Hurst ND, French JK, Gorjatschenko L, Betts WH. Studies on the mechanism of inhibition of chemotactic tripeptide stimulated human neutrophil polymorphonuclear leukocyte superoxide production by chloroquine and hydroxychloroquine. Ann Rheum Dis 1987; 45: 750-6.
16. Jančinová V, Májeková M, Nosál R, Petríková M. Inhibition of blood platelet functions by cationic amphiphilic drugs in relation to their physicochemical properties. Blood Coagul Fibrinolys 1996; 7: 191-3.
17. Jančinová V, Drábiková K, Nosál R, Danihelová E. Platelet-dependent modulation of polymorphonuclear leukocyte chemiluminescence. Platelets 2000; 11: 278-85.
18. Kihara H, Tishima H, Sogawa H, Nakagawa T. Stress and superoxide production by human neutrophils. Ann NY Acad Sci 1992; 650: 307-10.
19. 2 generation. Gen Physiol Biophys 1996; 15: 489-94.
20. Kotuliaková K, Drábiková K, Nosál R, Mačičková T, Danihelová E. Effect of cationic amphiphilic drug Dithiaden® on stimulated human polymorphonuclear cells. Scripta Med 1997; 70: 85-8.
21. Leino L, Lilius EM. Histamine receptors on leukocytes are expressed differentially in vitro and ex vivo. Int Arch Allergy Exp Immunol 1990; 91: 30-5.
22. 1 -antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exper Allergy 2002; 32: 489-98.
23. Liberman E, Schapiro JM, Feldman M, Arber L, Hod H, Berliner S et al. Time course analysis of the state of leukocyte adhesiveness/aggregation in patients with ischaemic heart disease. La Presse Med 1994; 23: 281-4.
24. Lojek A, Číž M, Marnila P, Dušková M, Lilius EM. Measurement of whole blood phagocyte chemiluminescence in the wistar rat. J Biolumin Chemilumin 1997; 12: 225-31.
25. 2 agonists on the chemiluminescence of human blood mononuclear cells induced by phytohemaglutinin. Immunopharmacol 1985; 9: 175-80.
26. 1 -histamine antagonist Dithiaden® inhibits stimulated platelet aggregation, malondialdehyde formation and thromboxane production in vitro. Inflamm Res 1995; 44: S14-5.
27. 1 -histamine antagonist Dithiaden® inhibits human platelet functions in vitro. Platelets 1997; 8: 175-80.
28. 2 : Toxicology and pharmacology. Biologia 2000; 55: 87-90.
29. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptors preferentially expressed in leukocytes. J Biol Chem 2000; 275: 36781-86.
30. Ozaki Y, Kume S, Ohashi T. Effects of histamine agonists and antagonists on luminol-dependent chemiluminescence of granulocytes. Agents Action 1984; 15: 182-8.
31. Perretti M, Harris JG, Flower RA. A role of endogenous histamine in interleukin-8-induced neutrophil infiltration into mouse air-pouch, investigation of the modulatory action of systemic and local dexamethasone. Br J Pharmacol 1994; 112: 801-8.
32. phox to activate the phagocyte NADPH oxidase. J Biol Chem 2000; 275: 13793-801.
33. Simon SI, Chambers JD, Sklar LA. Flow cytometric analysis and modeling of cell-cell adhesive interactions: The neutrophil as a model. J Cell Biol 1990; 111: 2747-56.
34. Steinbeck MJ, Hegg GC, Karnovsky MJ. Arachidonate activation of the neutrophil NADPH-oxidase. Synergistic effects of phosphatase inhibitors compared with protein kinase activators. J Biol Chem 1991; 266: 16336-42.
35. 1 receptor blocking drugs on metabolic activators on neutrophils. J Pharmacobio Dyn 1991; 14: 87-93.
36. Tarnok I, Tarnok Z. Interaction of cimetidine and histamine with superoxide generated in a cell-free system and in neutrophils. Agents Actions. 1987; 20: 324-6.
37. Tasaka K. Histamine and the blood In: Histamine and histamine antagonists. B. Uvnäs (Ed). Handbook of Experimental Pharmacology, vol 97, Springer-Verlag 1991, pp. 490-510.
38. Watson F. Phospholipases involved in activation of the neutrophil NADPH oxidase. Methods 1996; 9: 578-90.
39. White MW, Kaliner MA. Histamine. In: Inflammation: Basic Principles and Clinical Correlates. JI Gallin, IM Goldstein, R Synderman (Eds.) Raven Press, New York 1988; pp. 169-93.
40. Williams MA, Solomkin JS. Integrin-mediated signaling in human neutrophil functioning. J Leukocyt Biol 1999; 65: 725-36.